Last reviewed · How we verify
GRAPIPRANT
Grapiprant works by blocking the EP4 receptor, which is involved in pain and inflammation.
Grapiprant is a small molecule modality targeting the Prostaglandin E2 receptor EP4 subtype. Its mechanism of action involves selectively blocking the EP4 receptor, which plays a key role in inflammation and pain. Grapiprant is currently owned by Merial, a subsidiary of Boehringer Ingelheim, but its commercial status and approved indications are not specified. Further information on its pharmacokinetic properties, such as half-life and bioavailability, is also not available. As a result, its clinical use and safety profile remain unclear.
At a glance
| Generic name | GRAPIPRANT |
|---|---|
| Target | Prostaglandin E2 receptor EP4 subtype, Prostaglandin E2 receptor EP4 subtype |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | discontinued |
Mechanism of action
Think of the EP4 receptor like a messenger that tells your body to send pain signals. When Grapiprant blocks this messenger, it can help reduce pain and inflammation. This is similar to how other pain medications work, but Grapiprant targets a specific type of messenger that is involved in pain and inflammation.
Approved indications
Common side effects
Key clinical trials
- Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer (PHASE1,PHASE2)
- Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer (PHASE1)
- Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma (PHASE1,PHASE2)
- Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors (PHASE2)
- A Study Of The Effect Of CJ-023,423 On The Incidence Of Stomach Ulcers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GRAPIPRANT CI brief — competitive landscape report
- GRAPIPRANT updates RSS · CI watch RSS